Evidence map›Paper›PMID 41158376›Full record

ArticleJournal of thoracic disease2025

Intervention of traditional Chinese medicine San-Feng-Tong-Qiao-Di-Wan on allergic rhinitis: a network pharmacology and metabolomics study.

Huian Chen, Yongqing Xu, Xiaolong Deng, Haoqing Chen, Guanyu Yan, Jieya Peng, Jiaying Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huian ChenDepartment of Clinical Laboratory, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yongqing XuDepartment of Clinical Laboratory, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Xiaolong DengDepartment of Clinical Laboratory, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Haoqing ChenDepartment of Clinical Laboratory, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Guanyu YanDepartment of Clinical Laboratory, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jieya PengDepartment of Laboratory Medicine, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, China.
Jiaying LuoDepartment of Clinical Laboratory, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: San-Feng-Tong-Qiao-Di-Wan (SFTQDW) is a patented compound Chinese medicine used for acute and chronic rhinitis with few side effects. Its key components have antiallergic activity, making it potentially suitable for allergic rhinitis (AR). However, there is a lack of systematic research on its efficacy and mechanism of action for AR. This study aims to evaluate the potential and mechanism of SFTQDW in treating AR using network pharmacology, AR animal models, clinical observation, and serum metabolomics. Methods: Network pharmacology was used to screen active ingredients and targets, followed by an AR mouse model study comparing SFTQDW 3.00 Results: SFTQDW was found to target 16 allergy-related proteins in network pharmacology analysis. In an OVA-mouse model, the 3.00 mg/g dose of SFTQDW reduced sneezing frequency, nasal-rubbing bouts, serum immunoglobulin E (IgE) levels, nasal-tissue eosinophil counts, and goblet-cell hyperplasia more effectively than the 1.45 mg/g dose. In a clinical study with 32 adults, oral SFTQDW for 7 days improved VAS, RQLQ, and ESS scores. Serum metabolomics revealed 27 differentiated metabolites, with effects on linoleic acid metabolism and aminoacyl-tRNA biosynthesis. Conclusions: By possibly modulating the PTGS2/5(S)-HETE axis and its associated lipid inflammatory metabolites, SFTQDW helped alleviate nasal inflammation and acute symptoms in mice and patients.

Indexed as

allergic rhinitis (AR)metabolomicsnetwork pharmacologySan-Feng-Tong-Qiao-Di-Wan (SFTQDW)

Identifiers

PMID41158376
PMCPMC12557684

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.